Stock IQV IQVIA HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
234.9 USD +0.38% Intraday chart for Iqvia Holdings Inc. +2.98% +1.51%
Apr. 24 Market Share of Celltrion’s Remsima Rises to 74% in Europe MT
Apr. 22 RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 29,981 34,352 53,900 38,056 42,227 42,751 - -
Enterprise Value (EV) 1 40,789 44,983 64,659 49,587 54,524 54,809 54,370 53,326
P/E ratio 161 x 125 x 57 x 35.8 x 31.7 x 32.2 x 26.9 x 22.6 x
Yield - - - - - - - -
Capitalization / Revenue 2.7 x 3.02 x 3.88 x 2.64 x 2.82 x 2.75 x 2.56 x 2.39 x
EV / Revenue 3.68 x 3.96 x 4.66 x 3.44 x 3.64 x 3.53 x 3.26 x 2.98 x
EV / EBITDA 17 x 18.9 x 21.4 x 14.8 x 15.3 x 14.6 x 13.3 x 11.9 x
EV / FCF 48.8 x 33.5 x 28.1 x 31.3 x 36.3 x 31.6 x 25.5 x 22.2 x
FCF Yield 2.05% 2.99% 3.56% 3.2% 2.75% 3.16% 3.92% 4.51%
Price to Book 4.95 x 5.71 x 9.11 x 6.6 x 7.05 x 6.4 x 5.79 x 5.1 x
Nbr of stocks (in thousands) 194,038 191,726 191,040 185,740 182,500 182,014 - -
Reference price 2 154.5 179.2 282.1 204.9 231.4 234.9 234.9 234.9
Announcement Date 2/12/20 2/10/21 2/15/22 2/10/23 2/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,088 11,359 13,874 14,410 14,984 15,527 16,679 17,910
EBITDA 1 2,400 2,384 3,022 3,346 3,569 3,759 4,094 4,470
EBIT 1 2,112 2,030 2,591 2,779 3,050 3,148 3,455 3,778
Operating Margin 19.05% 17.87% 18.68% 19.29% 20.36% 20.27% 20.72% 21.1%
Earnings before Tax (EBT) 1 352 373 1,128 1,363 1,459 1,692 2,014 2,339
Net income 1 191 279 966 1,091 1,358 1,321 1,584 1,846
Net margin 1.72% 2.46% 6.96% 7.57% 9.06% 8.51% 9.5% 10.31%
EPS 2 0.9600 1.430 4.950 5.720 7.290 7.300 8.726 10.41
Free Cash Flow 1 835 1,343 2,302 1,586 1,500 1,734 2,129 2,407
FCF margin 7.53% 11.82% 16.59% 11.01% 10.01% 11.16% 12.76% 13.44%
FCF Conversion (EBITDA) 34.79% 56.33% 76.17% 47.4% 42.03% 46.12% 52% 53.84%
FCF Conversion (Net income) 437.17% 481.36% 238.3% 145.37% 110.46% 131.26% 134.38% 130.39%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/12/20 2/10/21 2/15/22 2/10/23 2/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 3,391 3,636 3,568 3,541 3,562 3,739 3,652 3,728 3,736 3,868 3,705 3,819 3,900 4,104 3,984
EBITDA 1 728 828 812 800 814 920 851 864 888 966 863.3 913.2 950 1,030 954.3
EBIT 1 623 704 691 682 694 712 721 737 747 821 727.7 775 802.2 875.5 804.6
Operating Margin 18.37% 19.36% 19.37% 19.26% 19.48% 19.04% 19.74% 19.77% 19.99% 21.23% 19.64% 20.3% 20.57% 21.34% 20.19%
Earnings before Tax (EBT) 1 273 376 400 328 360 275 362 375 349 373 357.8 403.2 431.8 504 409.3
Net income 1 261 318 325 256 283 227 289 297 303 469 283 316.5 340.3 399 325.5
Net margin 7.7% 8.75% 9.11% 7.23% 7.94% 6.07% 7.91% 7.97% 8.11% 12.13% 7.64% 8.29% 8.73% 9.72% 8.17%
EPS 2 1.340 1.630 1.680 1.340 1.490 1.200 1.530 1.590 1.630 2.540 1.482 1.718 1.847 2.153 1.805
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/21/21 2/15/22 4/27/22 7/21/22 10/26/22 2/10/23 4/27/23 8/1/23 11/1/23 2/14/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 10,808 10,631 10,759 11,531 12,297 12,057 11,619 10,575
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 4.503 x 4.459 x 3.56 x 3.446 x 3.446 x 3.207 x 2.838 x 2.366 x
Free Cash Flow 1 835 1,343 2,302 1,586 1,500 1,734 2,129 2,407
ROE (net income / shareholders' equity) 20.1% 20.9% 29.2% 32.8% 32% 31.2% 32.2% 34.6%
ROA (Net income/ Total Assets) 5.57% 1.17% 7.15% 7.74% 5.22% 6.3% 7.11% 8.32%
Assets 1 3,428 23,907 13,517 14,088 26,009 20,971 22,295 22,197
Book Value Per Share 2 31.20 31.40 31.00 31.00 32.80 36.70 40.60 46.00
Cash Flow per Share 2 7.100 10.00 15.10 11.90 11.50 14.00 17.10 18.90
Capex 1 582 616 640 674 649 657 687 744
Capex / Sales 5.25% 5.42% 4.61% 4.68% 4.33% 4.23% 4.12% 4.15%
Announcement Date 2/12/20 2/10/21 2/15/22 2/10/23 2/14/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Iqvia Holdings Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
234.9 USD
Average target price
275.4 USD
Spread / Average Target
+17.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IQV Stock
  4. Financials Iqvia Holdings Inc.